Novavax NVAX Transition Services — Total licensing, royalties, and other revenue

Similar metrics at other companies

AIPLicensing, support and maintenance — Total Revenue

$19.27M+25.7%

ABCLLicensing and royalty revenue — Total Revenue

$191K+14.4%

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

BCRXLicense and other revenues — Total revenues

$5.01M+187%

DLBLicensing — Total Revenue

$372.25M+7.6%

RCUSLicense and development services — Total revenues

$12M-40.0%

Questions, answered.

What is Novavax's transition services — total licensing, royalties, and other revenue?

Novavax (NVAX) reported transition services — total licensing, royalties, and other revenue of $45.4M in Q1 2026.

How has Novavax's transition services — total licensing, royalties, and other revenue changed year-over-year?

Novavax's transition services — total licensing, royalties, and other revenue increased by 12.7% year-over-year, from $40.3M to $45.4M.

What does transition services — total licensing, royalties, and other revenue mean?

This metric represents the total revenue generated from licensing intellectual property, royalty payments, and ancillary service agreements within the transition services segment. It reflects the company's ability to monetize its proprietary technology and partnerships without direct product sales. This is a key indicator of the segment's capacity to generate recurring, high-margin income streams.